EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?

Andreas Boehle, Dorothea Zywietz, Irina Robrahn-Nitschke, Inke R Koenig, Achim Lusch

Advances in Radiation Oncology · 2023-03 · 8 (2) · 101112

DOI: 10.1016/j.adro.2022.101112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Radiation Oncology, 2023-03. Verfasst von Andreas Boehle und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Luebeck, Luebeck, Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The aim of this study was to compare a surgical with a Phoenix-derived definition of cure at 4 years after treatment by 125J low-dose-rate brachytherapy (LDR-BT) in patients with low- and intermediate-risk prostate cancer. Methods and Materials: A total of 427 evaluable men with low-risk (62.8%) and intermediate-risk (37.2%) prostate cancer were treated with LDR-BT (160 Gy). Cure was defined at 4 years either as not having experienced a biochemical recurrence by the Phoenix definition, or by a surgical definition, using a posttreatment prostate-specific antigen of ≤0.2 ng/mL. Biochemical recurrence-free survival (BRFS), metastasis-free survival (MFS), and cancer-specific survival were calculated at 5 and 10 years using the Kaplan-Meier method. Standard diagnostic test evaluations were used to compare both definitions with regard to later metastatic failure or cancer-specific death.

Results

At 48 months, 427 patients were evaluable with a Phoenix-defined and 327 with a surgical-defined cure. At 5 and 10 years BRFS was 97.4% and 89% and MFS was 99.5% and 96.3% in the Phoenix-defined cure cohort, and BRFS was 98.2% and 92.7% and MFS was 100% and 99.4% in the surgical-defined cure cohort. Specificity for cure was 100% for both definitions. Sensitivity was 97.4% for the Phoenix and 96.3% for the surgical definition. The positive predictive value was 100% for both, whereas the negative predictive value was 29% for the Phoenix and 7.7% for the surgical definition. Accuracies of a correct prediction of cure were 94.8% and 96.3% for the Phoenix and the surgical definition, respectively.

Conclusions

Both definitions are useful for a reliable assessment of cure after LDR-BT in patients with low-risk and intermediate-risk prostate cancer. Cured patients might follow a less stringent follow-up schedule from 4 years onward, whereas patients not achieving cure at 4 years should be monitored for an extended time.

Autor:innen und Institutionen

  • Department of Urology, University of Luebeck, Luebeck, Germany.
  • HELIOS Agnes-Karll Hospital Bad Schwartau, Bad Schwartau, Germany.
  • CURAVID Radiology and Radiotherapy, Luebeck, Germany.
  • Institute for Medical Biometry and Statistics, University of Luebeck, Luebeck, Germany.

Zitieren

APA

Boehle, A., Zywietz, D., Robrahn-Nitschke, I., Koenig, I. R., & Lusch, A. (2023). Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?. Advances in Radiation Oncology, 8(2), 101112. https://doi.org/10.1016/j.adro.2022.101112

Vancouver

Boehle A, Zywietz D, Robrahn-Nitschke I, Koenig IR, Lusch A. Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?. Advances in Radiation Oncology. 2023;8(2):101112. doi:10.1016/j.adro.2022.101112

BibTeX
@article{Boehle2023,
  author = {Boehle, Andreas and Zywietz, Dorothea and Robrahn-Nitschke, Irina and Koenig, Inke R and Lusch, Achim},
  title = {Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?},
  journal = {Advances in Radiation Oncology},
  year = {2023},
  volume = {8},
  number = {2},
  pages = {101112},
  doi = {10.1016/j.adro.2022.101112}
}
Kostenlos starten →